March 10th, 2014
Selections from Richard Lehman’s Literature Review: March 10th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include cognitive function and brain structure in type 2 diabetics after intensive lowering of BP and lipid levels, the association of β-blocker therapy with risks of adverse CV events and deaths in those with ischemic heart disease undergoing noncardiac surgery, and more.
February 3rd, 2014
Intensive BP, Lipid Lowering Does Not Protect Against Cognitive Decline in Diabetics
Nicholas Downing, MD
Intensive treatment of blood pressure or cholesterol does not slow the rate of cognitive decline in adults with type 2 diabetes, according to a substudy of the ACCORD trial published in JAMA Internal Medicine. Some 3000 older adults with poorly controlled diabetes, high cardiovascular risk, and no evidence of cognitive impairment were assigned to one of […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?